RxDoctor Payments Data

Thomas Hensing, MD

Medical Oncology · Evanston, ILNPI 1932132743

Payments from drug & device makers

What this record shows

This record is dominated by education: $12 of the $12 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, E.r. Squibb & Sons, L.L.C.. That places this record below the midpoint for medical oncology clinicians in IL, where the typical reported total is $1,059.

$12in general payments, 2019–2025

Across 1 payment — averaging $11.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$12
$488,156in research payments, 2019–2025

Across 15 payments — averaging $32,544 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$472K
  • Helsinn Healthcare SA$16K

What the payments were for

  • Education$12100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.1$12

How this compares

$12 in reported general payments places this provider in the 5th percentile of 144 medical oncology providers in Illinois.

See all medical oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$52,653
Medicare patients
141
Services billed
663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate32$653,604
AlecensaAlectinib Hcl12$225,316
Erlotinib Hcl17$3,852
Dexamethasone40$665
Prochlorperazine Maleate35$248
Ondansetron Hcl23$131

Paid to pharmacies, not to this prescriber.

Other medical oncology in Evanston

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →